Sagimet Biosciences (SGMT) Operating Expenses (2022 - 2026)

Sagimet Biosciences' Operating Expenses history runs 5 years deep, the most recent figure standing at $11.7 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 41.04% year-over-year to $11.7 million; the TTM figure through Mar 2026 stood at $48.7 million (down 25.65% YoY), while the FY2025 annual figure was $56.9 million, up 4.47% from the prior year.
• Operating Expenses was $11.7 million for Q1 2026 at Sagimet Biosciences, up from $10.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $19.9 million in Q1 2025 to a low of $6.8 million in Q1 2023.
• Historically, Operating Expenses has averaged $11.1 million across 5 years, with a median of $10.0 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses jumped 126.56% in 2025, then slumped 41.04% in 2026.
• A 5-year view of Operating Expenses shows it stood at $7.4 million in 2022, then climbed by 28.13% to $9.5 million in 2023, then surged by 92.21% to $18.2 million in 2024, then sank by 40.84% to $10.8 million in 2025, then gained by 8.81% to $11.7 million in 2026.
• The last three Operating Expenses figures came in at $11.7 million (Q1 2026), $10.8 million (Q4 2025), and $14.3 million (Q3 2025), per Business Quant data.